{"filing":{"accession_number":"0001213900-26-068327","cik":"0001500198","ticker":"NMTC","company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"ea0294466-8k_neuroone.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1500198/000121390026068327/ea0294466-8k_neuroone.htm"},"events":[{"id":10318,"run_id":9048,"accession_number":"0001213900-26-068327","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"The Company filed an updated Prospectus Supplement on June 12, 2026, authorizing the sale of up to $13.4 million of common shares through an at-the-market (ATM) offering program with JonesTrading. ATM offerings represent dilutive equity issuances that can be executed at management's discretion, which is a material event requiring disclosure under Item 3.02 (or Item 8.01 as here). The specific dollar amount and mechanism indicate a material capital-raising activity.","company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":6606,"accession_number":"0001213900-26-068327","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Company filed an updated Prospectus Supplement on June 12, 2026, authorizing the sale of up to $13.4 million of common shares through an at-the-market (ATM) offering program with JonesTrading. ATM offerings represent dilutive equity issuances that can be executed at management's discretion, which is a material event requiring disclosure under Item 3.02 (or Item 8.01 as here). The specific dollar amount and mechanism indicate a material capital-raising activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:02:43.714633+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6606,"accession_number":"0001213900-26-068327","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Company filed an updated Prospectus Supplement on June 12, 2026, authorizing the sale of up to $13.4 million of common shares through an at-the-market (ATM) offering program with JonesTrading. ATM offerings represent dilutive equity issuances that can be executed at management's discretion, which is a material event requiring disclosure under Item 3.02 (or Item 8.01 as here). The specific dollar amount and mechanism indicate a material capital-raising activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:02:43.714633+00:00","company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","filing_date":"2026-06-12"}]}